Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death - PubMed (original) (raw)
. 2014 Oct 21;111(42):15072-7.
doi: 10.1073/pnas.1408987111. Epub 2014 Oct 6.
Maria C Tanzer 1, Isabelle S Lucet 2, Samuel N Young 3, Sukhdeep K Spall 3, Pooja Sharma 1, Catia Pierotti 3, Jean-Marc Garnier 1, Renwick C J Dobson 4, Andrew I Webb 1, Anne Tripaydonis 1, Jeffrey J Babon 1, Mark D Mulcair 5, Martin J Scanlon 5, Warren S Alexander 1, Andrew F Wilks 6, Peter E Czabotar 1, Guillaume Lessene 7, James M Murphy 8, John Silke 8
Affiliations
- PMID: 25288762
- PMCID: PMC4210347
- DOI: 10.1073/pnas.1408987111
Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death
Joanne M Hildebrand et al. Proc Natl Acad Sci U S A. 2014.
Abstract
Necroptosis is considered to be complementary to the classical caspase-dependent programmed cell death pathway, apoptosis. The pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) is an essential effector protein in the necroptotic cell death pathway downstream of the protein kinase Receptor Interacting Protein Kinase-3 (RIPK3). How MLKL causes cell death is unclear, however RIPK3-mediated phosphorylation of the activation loop in MLKL trips a molecular switch to induce necroptotic cell death. Here, we show that the MLKL pseudokinase domain acts as a latch to restrain the N-terminal four-helix bundle (4HB) domain and that unleashing this domain results in formation of a high-molecular-weight, membrane-localized complex and cell death. Using alanine-scanning mutagenesis, we identified two clusters of residues on opposing faces of the 4HB domain that were required for the 4HB domain to kill cells. The integrity of one cluster was essential for membrane localization, whereas MLKL mutations in the other cluster did not prevent membrane translocation but prevented killing; this demonstrates that membrane localization is necessary, but insufficient, to induce cell death. Finally, we identified a small molecule that binds the nucleotide binding site within the MLKL pseudokinase domain and retards MLKL translocation to membranes, thereby preventing necroptosis. This inhibitor provides a novel tool to investigate necroptosis and demonstrates the feasibility of using small molecules to target the nucleotide binding site of pseudokinases to modulate signal transduction.
Keywords: ATP mimetic; RIP kinase; programmed necrosis; pseudoenzyme.
Conflict of interest statement
Conflict of interest statement: J.S. is a member of the Scientific Advisory Board of Tetralogic Pharmaceuticals. A.F.W. is Chair of SynThesis MedChem and a Director of Catalyst Therapeutics.
Figures
Fig. 1.
The 4HB domain of MLKL is sufficient to induce necroptosis. (A) Schematic representing the different constructs used and the corresponding MLKL structure. (B–L) MDF cell lines derived from wild-type or Mlkl −/− mice were stably infected with the indicated MLKL constructs. MLKL variants were induced for 4 h (white bars) or not (black bars), then either left untreated (UT) or treated with the apoptotic stimulus (TS) or necroptotic stimulus (TSQ) for 24 h. Q, Q-VD-OPh; S, Smac-mimetic; T, TNF. PI-permeable cells were quantified using flow cytometry. (G) As above, but in addition, cells were also treated with N, Necrostatin-1. Data are plotted as the mean ± SEM of at least two biological replicates each assayed in a minimum of three independent experiments.
Fig. 2.
Residues required for 4HB killing cluster into two motifs. (A) Alignment of MLKL orthologs. Groups of mutated residues are indicated by lowercase letters. Residues in red when mutated to Alanine prevented 4HB killing in both _Mlkl_−/− and wild-type cells; mutation of residues highlighted in orange prevented 4HB killing in _Mlkl_−/− but not wild-type cells. (B) Three biologically independent MDF cell lines derived from Mlkl −/− mice were stably infected with the indicated doxycycline-inducible 4HB MLKL wild-type and mutant constructs and each assayed in two independent experiments. Cell lines were induced for 20 h (white bars) or not (black bars) before viability was quantitated. All data are plotted as mean ± SEM. (C) Depiction of the 4HB domain (Protein Data Bank ID code 4BTF) (1) drawn using PyMOL software with residues colored according to the scheme in panel A.
Fig. 3.
MLKL and the 4HB domain of MLKL form high-molecular-weight complexes in biological membranes. (A) Blue-Native PAGE showed that endogenous MLKL translocated from cytoplasm (C) to membrane (M) fraction in wild-type MDFs following TSQ treatment. (B) MLKL(1–180) similarly translocated to the membranes of Mlkl −/− MDFs following induction. (C) Recombinant MLKL(1–169) resolved by Blue-Native PAGE. (D) Membrane complex (complex II) formation monitored by Blue-Native PAGE after a 6-h induction of wild-type MLKL(1–180), _N_-FLAG–tagged MLKL(1–180), cluster 2 mutants (Y15A/E16A and C18S/C24S/C28S), and cluster 1 mutants (R63A/D65A, E102A/K103A, R105A/D105A, E109A/E110A, and LLLL112–115AAAA). Data presented were obtained from three independent experiments performed on two biological replicate cell lines.
Fig. 4.
Compound 1, a small molecule targeting the nucleotide binding site of the MLKL pseudokinase domain, retards MLKL membrane translocation and inhibits necroptosis. (A and B) Compound 1 was identified as an MLKL interactor using a thermal stability shift assay. (C) Compound 1 binding to the MLKL pseudokinase domain was validated by SPR. Sensorgrams show the kinetics of compound 1 binding (at a given concentration from 6.25 to 200 µM) to MLKL (colored curves) with fit to model overlaid (black curves). x axis, time (s); y axis, response unit (RU) levels. (D) Compound 1 and Nec-1 inhibited necroptotic death of wild-type MDFs stimulated with TSQ (1 ng/mL TNF, 500 nM compound A, 10 μM Q-VD-OPh) in a dose-dependent manner. Data shown are the mean ± SEM for three independent experiments. (E) Compound 1 (1 μM) retarded MLKL translocation to the membrane. Cytoplasmic and membrane fraction purity and protein abundance are illustrated by control blots for GAPDH and VDAC1. Data are representative of three independent repeats. (F) A model for MLKL activation and the mechanism of action of compound 1.
Similar articles
- The brace helices of MLKL mediate interdomain communication and oligomerisation to regulate cell death by necroptosis.
Davies KA, Tanzer MC, Griffin MDW, Mok YF, Young SN, Qin R, Petrie EJ, Czabotar PE, Silke J, Murphy JM. Davies KA, et al. Cell Death Differ. 2018 Sep;25(9):1567-1580. doi: 10.1038/s41418-018-0061-3. Epub 2018 Feb 14. Cell Death Differ. 2018. PMID: 29445128 Free PMC article. - Identification of MLKL membrane translocation as a checkpoint in necroptotic cell death using Monobodies.
Petrie EJ, Birkinshaw RW, Koide A, Denbaum E, Hildebrand JM, Garnish SE, Davies KA, Sandow JJ, Samson AL, Gavin X, Fitzgibbon C, Young SN, Hennessy PJ, Smith PPC, Webb AI, Czabotar PE, Koide S, Murphy JM. Petrie EJ, et al. Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8468-8475. doi: 10.1073/pnas.1919960117. Epub 2020 Mar 31. Proc Natl Acad Sci U S A. 2020. PMID: 32234780 Free PMC article. - Necroptosis signalling is tuned by phosphorylation of MLKL residues outside the pseudokinase domain activation loop.
Tanzer MC, Tripaydonis A, Webb AI, Young SN, Varghese LN, Hall C, Alexander WS, Hildebrand JM, Silke J, Murphy JM. Tanzer MC, et al. Biochem J. 2015 Oct 15;471(2):255-65. doi: 10.1042/BJ20150678. Epub 2015 Aug 17. Biochem J. 2015. PMID: 26283547 - A tale of two domains - a structural perspective of the pseudokinase, MLKL.
Czabotar PE, Murphy JM. Czabotar PE, et al. FEBS J. 2015 Nov;282(22):4268-78. doi: 10.1111/febs.13504. Epub 2015 Sep 25. FEBS J. 2015. PMID: 26337687 Review. - The web of death: the expanding complexity of necroptotic signaling.
Horne CR, Samson AL, Murphy JM. Horne CR, et al. Trends Cell Biol. 2023 Feb;33(2):162-174. doi: 10.1016/j.tcb.2022.05.008. Epub 2022 Jun 21. Trends Cell Biol. 2023. PMID: 35750616 Review.
Cited by
- A kinase fusion protein from Aegilops longissima confers resistance to wheat powdery mildew.
He H, Chen Z, Fan R, Zhang J, Zhu S, Wang J, Zhang Q, Gao A, Gong S, Zhang L, Li Y, Zhao Y, Krattinger SG, Shen QH, Li H, Wang Y. He H, et al. Nat Commun. 2024 Aug 2;15(1):6512. doi: 10.1038/s41467-024-50909-6. Nat Commun. 2024. PMID: 39095395 Free PMC article. - Regulation of RIPK1 Phosphorylation: Implications for Inflammation, Cell Death, and Therapeutic Interventions.
Du J, Wang Z. Du J, et al. Biomedicines. 2024 Jul 9;12(7):1525. doi: 10.3390/biomedicines12071525. Biomedicines. 2024. PMID: 39062098 Free PMC article. Review. - HSPA8 inhibitors augment cancer chemotherapeutic effectiveness via potentiating necroptosis.
Wu E, Wu C, Jia K, Zhou S, Sun L. Wu E, et al. Mol Biol Cell. 2024 Aug 1;35(8):ar108. doi: 10.1091/mbc.E24-04-0194. Epub 2024 Jul 3. Mol Biol Cell. 2024. PMID: 38959101 - Mitochondria and cell death.
Glover HL, Schreiner A, Dewson G, Tait SWG. Glover HL, et al. Nat Cell Biol. 2024 Sep;26(9):1434-1446. doi: 10.1038/s41556-024-01429-4. Epub 2024 Jun 20. Nat Cell Biol. 2024. PMID: 38902422 Review. - RISING STARS: Evidence for established and emerging forms of β-cell death.
Colglazier KA, Mukherjee N, Contreras CJ, Templin AT. Colglazier KA, et al. J Endocrinol. 2024 Jul 4;262(2):e230378. doi: 10.1530/JOE-23-0378. Print 2024 Aug 1. J Endocrinol. 2024. PMID: 38842911 Free PMC article. Review.
References
- Murphy JM, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39(3):443–453. - PubMed
- Newton K, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343(6177):1357–1360. - PubMed
- He S, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137(6):1100–1111. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous